Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:CYCCP

Cyclacel Pharmaceuticals (CYCCP) Stock Price, News & Analysis

Cyclacel Pharmaceuticals logo

About Cyclacel Pharmaceuticals Stock (NASDAQ:CYCCP)

Advanced Chart

Key Stats

Today's Range
$5.30
$5.30
50-Day Range
$5.00
$6.03
52-Week Range
$3.29
$17.00
Volume
1 shs
Average Volume
5,122 shs
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
11.94%
Price Target
N/A
Consensus Rating
N/A

Company Overview

Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company's oncology development programs include fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase I clinical trial for the treatment of solid tumors, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and CYC140, a polo-like kinase inhibitor program, which is in Phase I clinical trial for the treatment of advanced leukemias. Its oncology development programs also comprise Sapacitabine, an orally available prodrug of CNDAC, which is a novel nucleoside analog. In addition, the company's oncology development programs include seliciclib, a CDK inhibitor. It has a clinical collaboration agreement with the University of Texas MD Anderson Cancer Center to clinically evaluate the safety and efficacy of three cyclacel medicines in patients with hematological malignancies, including chronic lymphocytic leukemias, acute myeloid leukemias, myelodysplastic syndromes, and other advanced leukemias. Cyclacel Pharmaceuticals, Inc. was founded in 1992 and is headquartered in Berkeley Heights, New Jersey.

Receive CYCCP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cyclacel Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

CYCCP Stock News Headlines

Cyclacel Pharmaceuticals, Inc. (CYCC) - Yahoo Finance
New Rule Hits in July — The Smart Money Already Moved
A little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Street and the Big Banks… It gives them the green light to treat a certain tangible asset as equivalent to cold, hard cash. Not stocks. Not real estate. And definitely not the U.S. dollar. We're talking about something they don't want you to notice — because the fewer people who act on this, the better it is for them.
CYCLACEL PHARMACEUTICALS ANNOUNCES STOCK SPLIT
See More Headlines

Company Calendar

Record date for 5/1 Dividend
4/29/2025
Ex-Dividend for 5/1 Dividend
4/29/2025
Dividend Payable
5/01/2025
Today
6/30/2025
Record date for 8/1 Dividend
7/21/2025
Ex-Dividend for 8/1 Dividend
7/21/2025
Dividend Payable
8/01/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
Current Symbol
NASDAQ:CYCCP
Fax
N/A
Employees
12
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Price / Book
N/A

Miscellaneous

Free Float
N/A
Optionable
Not Optionable
Beta
N/A
A Beginner's Guide to Investing in Cannabis Cover

Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.

Get This Free Report

This page (NASDAQ:CYCCP) was last updated on 7/1/2025 by MarketBeat.com Staff
From Our Partners